This page shows the latest Blueprint Medicines news and features for those working in and with pharma, biotech and healthcare.
FDA) and the European Medicines Agency (EMA). ... The positive readout comes just a few weeks after Roche’s Genentech unit and Blueprint Medicines received full approval from the FDA for use of their targeted cancer therapy, Gavreto (pralsetinib),
The latest results for Retevmo come just a few weeks after Roche said it would be withdrawing its Blueprint Medicines-partnered Gavreto (pralsetinib) from the US RET-mutant MTC market, citing
Roche’s Genentech unit and Blueprint Medicines have received full approval from the US Food and Drug Administration (FDA) for use of their targeted cancer therapy, Gavreto (pralsetinib), in a subset ... Gavreto was jointly developed and commercialised
The US Food and Drug Administration (FDA) has approved Blueprint Medicines’ Ayvakit (avapritinib) as the first and only medicine designed to treat indolent systemic mastocytosis (ISM). ... Blueprint’s chief medical officer, Becker Hewes, said the
Expands on initial deal that is worth up to $1bn. Roche has expanded its existing collaboration with Blueprint Medicines, signing a new deal which will see it gain rights to the ... development of pralsetinib across multiple treatment settings where
for Blueprint Medicines’ BLU-782, an ALK2 inhibitor in phase 1 development for the treatment of FOP.
More from news
Approximately 7 fully matching, plus 5 partially matching documents found.
And Blueprint Medicines created a proprietary PRO for its mastocytosis drug. ... Blueprint Medicines is one company that took matters into its own hands.
Open Conversations: Pathway to Launch Excellence It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
Open Conversations: Pathway to Launch Excellence. It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
Roche has paid $45m upfront with $965m in contingent fees, including options, milestones and royalties for the rights to up to five small molecules from Blueprint Medicines' drug discovery platform. ... Acquisition of royalty rights. $1, 140. Blueprint
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
No results were found
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...